1
|
Makita-Chingombe F, Podany AT, Mykris T, Muzambi F, Browne RW, Ocque AJ, DiFrancesco R, Winchester LC, Fletcher CV, Mudzviti T, Maponga CC, Morse GD. Cross-validation of a high-performance liquid chromatography nevirapine plasma assay in a resource-limited setting in Zimbabwe. Afr J Lab Med 2021; 10:1264. [PMID: 34395199 PMCID: PMC8335789 DOI: 10.4102/ajlm.v10i1.1264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2020] [Accepted: 02/24/2021] [Indexed: 11/02/2022] Open
Abstract
An international HIV pharmacology specialty laboratory (PSL) was established at the University of Zimbabwe to increase bioanalytical and investigator capacities. Quantitation of plasma nevirapine in samples from the AIDS Clinical Trials Group protocol 5279 was compared between the University of Nebraska Medical Center PSL and the University of Zimbabwe PSL. Both PSLs employed internally developed methods utilising reverse-phase high-performance liquid chromatography with ultraviolet detection. Eighty-seven percent of the cross-validation results exhibited ± 20% difference.
Collapse
Affiliation(s)
- Faithful Makita-Chingombe
- International Pharmacology Specialty Laboratory, School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - Anthony T Podany
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, United States
| | - Timothy Mykris
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, United States
| | - Farai Muzambi
- International Pharmacology Specialty Laboratory, School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - Richard W Browne
- Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States
| | - Andrew J Ocque
- Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States
| | - Robin DiFrancesco
- Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States
| | - Lee C Winchester
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, United States
| | - Courtney V Fletcher
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, United States
| | - Tinashe Mudzviti
- International Pharmacology Specialty Laboratory, School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe
| | - Charles C Maponga
- International Pharmacology Specialty Laboratory, School of Pharmacy, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe.,Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States
| | - Gene D Morse
- Translational Pharmacology Research Core, Center for Integrated Global Biomedical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, United States
| |
Collapse
|
2
|
Fletcher CV, Podany AT, Thorkelson A, Winchester LC, Mykris T, Anderson J, Jorstad S, Baker JV, Schacker TW. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons. Clin Pharmacol Ther 2020; 108:971-975. [PMID: 32385902 DOI: 10.1002/cpt.1883] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Accepted: 04/22/2020] [Indexed: 01/12/2023]
Abstract
The secondary lymphoid tissues (LT), lymph nodes (LN) and gut-associated lymphoid tissue are the primary sites of HIV replication and where the latent pool of virus is maintained. We compared the pharmacokinetics of tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) in LT of 13 HIV-infected persons receiving a TDF-containing antiretroviral regimen who subsequently switched to a TAF-containing regimen. Study participants were on stable antiretroviral therapy for ≥12 months with plasma HIV-RNA < 48 copies/mL for 6 months before enrollment and entry CD4 cell counts > 300 cells/µL. Intracellular concentrations of tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) were quantified in PBMCs and in mononuclear cells obtained from LN, ileum and rectal tissues. With TAF, the TFV-DP concentrations in PBMCs and LN were 7.3-fold and 6.4-fold higher (ratios of geometric means of TAF to TDF), respectively, compared with TDF; ileal and rectal concentrations, however, were lower with geometric mean ratios of 0.14 and 0.18, respectively. A statistically significant relationship was observed between PBMC and LN concentrations of TFV-DP. During TDF-containing therapy, the expected effect of cobicistat to increase TFV plasma concentrations was observed, as were higher TFV-DP concentrations in PBMCs and mononuclear cells from LN, ileum and rectal tissues. The higher TFV-DP concentrations achieved with TAF in the LN provides the first human correlate of the observation in animals that TAF produced higher tenofovir LN concentrations. The ability to increase LN concentrations allows investigations of whether antiretroviral regimens with improved LN pharmacokinetics elicit a more complete virologic response in that compartment.
Collapse
Affiliation(s)
- Courtney V Fletcher
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Anthony T Podany
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Ann Thorkelson
- Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| | - Lee C Winchester
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Timothy Mykris
- Antiviral Pharmacology Laboratory, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Jodi Anderson
- Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| | - Siri Jorstad
- Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| | - Jason V Baker
- Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.,Infectious Diseases, Hennepin Healthcare Research Institute (HHRI), Minneapolis, Minnesota, USA
| | - Timothy W Schacker
- Division of Infectious Diseases, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA
| |
Collapse
|